Proactive Investors - Run By Investors For Investors

Instem secures US$750,000 contract with Fortune 500 heavyweight

Phil Reason, chief executive of Instem Plc (LON:INS), tells Proactive Investors a Fortune 500 medical products and pharma company has adopted its Samarind Regulatory Management System.

The deal is worth an initial US$750,000, with 80% of that sum being recognised this year, and brings with it recurring annual revenues of US$169,000.

Meet Faron Pharmaceuticals Ltd, Belvoir Lettings and Silence Therapeutics PLC at our event, London , 23 May 2019. Register here »
View full INS profile View Profile

Instem PLC Timeline

April 11 2019
April 01 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use